We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+6.67%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$424M
AUM Growth
+$63.8M
Cap. Flow
+$65.2M
Cap. Flow %
15.39%
Top 10 Hldgs %
48.45%
Holding
91
New
14
Increased
28
Reduced
11
Closed
21

Top Buys

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$21.9M
2
ERAS icon
Erasca
ERAS
+$16.4M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$10.9M
4
URGN icon
UroGen Pharma
URGN
+$8.44M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$7.74M

Top Sells

Rank Stock Value
1
CATX icon
Perspective Therapeutics
CATX
+$7.96M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$7.89M
3
SLDB icon
Solid Biosciences
SLDB
+$7.63M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$5.98M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$5.83M

Sector Composition

Rank Sector Weight
1 Healthcare 95.56%
2 Miscellaneous 4.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$36.9M 8.71%
623,628
+57,341
+10% +$2.78M
NUVL
2
DELISTED
Nuvalent
NUVL
$35.3M 8.33%
465,710
+307,960
+195% +$21.9M
RNAM
3
DELISTED
Avidity Biosciences
RNAM
$21.1M 4.99%
517,734
+28,431
+6% +$816K
URGN icon
4
UroGen Pharma
URGN
$2.13B
$18.5M 4.36%
1,102,000
+593,413
+117% +$8.44M
ERAS icon
5
Erasca
ERAS
$6.31B
$18.4M 4.35%
7,816,926
+7,593,081
+3,392% +$16.4M
INSM icon
6
CALL
Insmed
INSM
$25.9B
$16.8M 3.95%
+250,000
New +$9.7M
MORF
7
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$16.6M 3.91%
486,306
+2,334
+0.5% +$69.1K
AKRO
8
DELISTED
Akero Therapeutics
AKRO
$14.7M 3.46%
625,087
+225,138
+56% +$4.81M
CLDX icon
9
Celldex Therapeutics
CLDX
$3.07B
$13.9M 3.27%
374,910
+75,594
+25% +$2.85M
ITCI
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$13.2M 3.11%
192,345
+157,538
+453% +$10.9M
PSTX
11
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$10.5M 2.49%
3,607,999
+11,523
+0.3% +$31.5K
COGT icon
12
Cogent Biosciences
COGT
$6.02B
$10.2M 2.4%
1,206,214
+169,547
+16% +$1.29M
INSM icon
13
Insmed
INSM
$25.9B
$9.38M 2.21%
140,000
+26,384
+23% +$1.02M
ALNY icon
14
Alnylam Pharmaceuticals
ALNY
$31.7B
$8.75M 2.06%
+36,000
New +$5.68M
ELUT icon
15
Elutia
ELUT
$39M
$7.95M 1.88%
1,603,580
+1,525,000
+1,941% +$4.96M
CRBP icon
16
Corbus Pharmaceuticals
CRBP
$211M
$7.81M 1.84%
172,492
+140,512
+439% +$5.91M
ORIC icon
17
Oric Pharmaceuticals
ORIC
$1.37B
$7.61M 1.79%
1,075,812
-37,195
-3% -$333K
SNDX icon
18
Syndax Pharmaceuticals
SNDX
$1.74B
$7.6M 1.79%
+370,000
New +$7.74M
RYTM icon
19
Rhythm Pharmaceuticals
RYTM
$7.38B
$7.58M 1.79%
184,662
+886
+0.5% +$35.4K
CCCC icon
20
C4 Therapeutics
CCCC
$474M
$6.67M 1.57%
1,442,841
+6,910
+0.5% +$41.2K
SRPT icon
21
Sarepta Therapeutics
SRPT
$2.2B
$6.64M 1.57%
+42,000
New +$5.4M
KALV
22
DELISTED
KalVista Pharmaceuticals
KALV
$6.61M 1.56%
560,883
-300
-0.1% -$3.5K
VCYT icon
23
Veracyte
VCYT
$3.48B
$6.12M 1.44%
282,248
+1,475
+0.5% +$31K
ABVX
24
Abivax
ABVX
$9.89B
$6.03M 1.42%
455,800
+380,800
+508% +$5.45M
OLMA icon
25
Olema Pharmaceuticals
OLMA
$899M
$5.92M 1.4%
546,863
+31,546
+6% +$342K
1
2 3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Silverarc Capital Management held 91 positions worth $424M, up 18% from $360M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Silverarc Capital Management deployed $65.2M of net new capital in Q2 2024, opening 14 new positions and adding to 28 existing holdings. Its largest new stake was Syndax Pharmaceuticals: 370,000 shares worth $7.6M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Perspective Therapeutics, an estimated $7.96M trimmed.

  • Silverarc Capital Management's largest Q2 2024 buy was Syndax Pharmaceuticals: 370,000 shares worth $7.6M.
  • Silverarc Capital Management added most to Nuvalent in Q2 2024, an estimated $21.9M increase.
  • Silverarc Capital Management's biggest Q2 2024 reduction was Perspective Therapeutics, cutting an estimated $7.96M.
  • Silverarc Capital Management fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $7.89M.
  • Silverarc Capital Management's ten largest holdings make up 48% of its $424M portfolio in Q2 2024.
  • Silverarc Capital Management opened 14 new positions and closed 21 in Q2 2024.
  • Silverarc Capital Management's portfolio value rose 18% quarter-over-quarter to $424M.

Based on Silverarc Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.